eprintid: 19353
rev_number: 39
eprint_status: archive
userid: 1589
dir: disk0/00/01/93/53
datestamp: 2015-11-25 14:14:46
lastmod: 2024-02-29 17:47:03
status_changed: 2015-11-25 14:14:46
type: article
metadata_visibility: show
creators_name: Dreikhausen, Lena
creators_name: Blank, Susanne
creators_name: Sisic, Leila
creators_name: Heger, Ulrike
creators_name: Weichert, Wilko
creators_name: Jäger, Dirk
creators_name: Bruckner, Thomas
creators_name: Giese, Natalia
creators_name: Grenacher, Lars
creators_name: Falk, Christine
creators_name: Ott, Katja
creators_name: Schmidt, Thomas
title: Association of angiogenic factors with prognosis in esophageal cancer
subjects: ddc-610
divisions: i-910200
divisions: i-911400
divisions: i-911800
divisions: i-912000
abstract: Background: Despite multimodal therapy esophageal cancer often presents with poor prognosis. To improve outcome, tumor angiogenesis and anti-angiogenic therapeutic agents have recently gained importance. However, patient subgroups who benefit from anti-angiogenic therapy are not yet defined. In this retrospective exploratory study we investigated 9 angiogenic factors in patients’ serum and tissue samples with regard to their association with clinicopathological parameters, prognosis and response in patients with locally advanced preoperatively treated esophageal cancer.   Methods: From 2007 to 2012 preoperative serum and corresponding tumor tissue (n = 54), only serum (n = 20) or only tumor tissue (n = 4) were collected from esophageal squamous cell carcinoma (SCC) (n = 34) and adenocarcinoma of the esophagogastric junction (AEG) (n = 44) staged cT3/4NanyM0/x after preoperative chemo(radio)therapy. Angiogenic cytokine levels in both tissue and serum were measured by multiplex immunoassay.   Results: Median survival in all patients was 28.49 months. No significant difference was found in survival between SCC and AEG (p = 0.90). 26 patients were histopathological responders. Histopathological response was associated with prognosis (p = 0.05). Angiogenic factors were associated with the following clinicopathological factors: tumor tissue expression of Angiopoietin-2 and Follistatin was higher in SCC compared to AEG (p = 0.022 and p = 0.001). High HGF and Follistatin expression in the tumor tissue was associated with poor prognosis in all patients (p = 0.037 and p = 0.036). No association with prognosis was found in the patients’ serum. Neither patients’ serum nor tumor tissue showed an association between angiogenic factors and response to neoadjuvant therapy.   Conclusion: Two angiogenic factors (HGF and Follistatin) in posttherapeutic tumor tissue are associated with prognosis in esophageal cancer patients. Biological differences of AEG and SCC with respect to angiogenesis were evident by the different expression of 2 angiogenic factors. Results are promising and should be pursued prospectively, optimally sequentially pre- and posttherapeutically.  
date: 2015
publisher: BioMed Central
id_scheme: DOI
ppn_swb: 453413331
own_urn: urn:nbn:de:bsz:16-heidok-193537
language: eng
bibsort: DREIKHAUSEASSOCIATIO2015
full_text_status: public
publication: BMC cancer
volume: 15
number: 121
place_of_pub: London
pagerange: 1-11
issn: 1471-2407
citation:   Dreikhausen, Lena ; Blank, Susanne ; Sisic, Leila ; Heger, Ulrike ; Weichert, Wilko ; Jäger, Dirk ; Bruckner, Thomas ; Giese, Natalia ; Grenacher, Lars ; Falk, Christine ; Ott, Katja ; Schmidt, Thomas  (2015) Association of angiogenic factors with prognosis in esophageal cancer.  BMC cancer, 15 (121).  pp. 1-11.  ISSN 1471-2407     
document_url: https://archiv.ub.uni-heidelberg.de/volltextserver/19353/1/12885_2015_Article_1120.pdf